MedTrace Logo

Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

NCT05708157 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2023-02-01

No results posted yet for this study

Summary

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale \[VAS\] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

concomitant intranasal antihistamine and corticosteroid

concomitant intranasal administration with antihistamine and corticosteroid

Sponsors & Collaborators

  • Hallym University Kangnam Sacred Heart Hospital

    collaborator OTHER

  • Gangneung Asan Hospital

    collaborator OTHER

  • Bundang Jesaeng Hospital

    collaborator UNKNOWN

  • Chung-Ang University Gwangmyeong Hospital

    collaborator OTHER

  • Hallym University Medical Center

    collaborator OTHER

  • Gachon University Gil Medical Center

    lead OTHER

Principal Investigators

  • Sang Min Lee, MD, PhD · Gachon University Gil Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05708157 on ClinicalTrials.gov